Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer
AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer
AstraZeneca and Merck establish strategic oncology collaboration
H1 2017 Results
Faslodex receives EU approval as first-line therapy for advanced breast cancer
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development